An important role for adenine, cholera toxin, hydrocortisone and triiodothyronine in the proliferation, self-renewal and differentiation of limbal stem cells in vitro.
The cornea is a self-renewing tissue located at the front of the eye. Its transparency is essential for allowing light to focus onto the retina for visual perception. The continuous renewal of corneal epithelium is supported by limbal stem cells (LSCs) which are located in the border region between conjunctiva and cornea known as the limbus. Ex vivo expansion of LSCs has been successfully applied in the last two decades to treat patients with limbal stem cell deficiency (LSCD). Various methods have been used for their expansion, yet the most widely used culture media contains a number of ingredients derived from animal sources which may compromise the safety profile of human LSC transplantation. In this study we sought to understand the role of these components namely adenine, cholera toxin, hydrocortisone and triiodothyronine with the aim of re-defining a safe and GMP compatible minimal media for the ex vivo expansion of LSCs on human amniotic membrane. Our data suggest that all four components play a critical role in maintaining LSC proliferation and promoting LSC self-renewal. However removal of adenine and triiodothyronine had a more profound impact and led to LSC differentiation and loss of viability respectively, suggesting their essential role for ex vivo expansion of LSCs. Replacement of each of the components with GMP-grade reagents resulted in equal growth to non-GMP grade media, however an enhanced differentiation of LSCs was observed, suggesting that additional combinations of GMP grade reagents need to be tested to achieve similar or better level of LSC maintenance in the same manner as the traditional LSC media.
Institute of Genetic Medicine, Newcastle University, UK.
Min
M
Yu
Institute of Genetic Medicine, Newcastle University, UK.
Sanja
S
Bojic
Institute of Genetic Medicine, Newcastle University, UK; Department of Ophthalmology, Royal Victoria Infirmary, Newcastle University, UK.
Gustavo S
GS
Figueiredo
NHS Blood and Transplant, UK.
Paul
P
Rooney
Institute of Cellular Medicine, Newcastle University, UK.
Julian
J
de Havilland
Institute of Cellular Medicine, Newcastle University, UK.
Anne
A
Dickinson
Institute of Genetic Medicine, Newcastle University, UK; Department of Ophthalmology, Royal Victoria Infirmary, Newcastle University, UK.
Francisco C
FC
Figueiredo
Institute of Genetic Medicine, Newcastle University, UK. Electronic address: Majlinda.Lako@ncl.ac.uk.
Majlinda
M
Lako
D000225:Adenine / Q000378:metabolism*; D002102:Cadaver; D002452:Cell Count; D018929:Cell Culture Techniques; D002454:Cell Differentiation; D002478:Cells, Cultured; D002772:Cholera Toxin / Q000378:metabolism*; D003316:Corneal Diseases / Q000378:metabolism / Q000473:pathology / Q000601:surgery; D003470:Culture Media; D004247:DNA / Q000235:genetics; D006801:Humans; D006854:Hydrocortisone / Q000378:metabolism*; D007150:Immunohistochemistry; D016850:Limbus Corneae / Q000166:cytology* / Q000378:metabolism; D008875:Middle Aged; D020133:Reverse Transcriptase Polymerase Chain Reaction; D033581:Stem Cell Transplantation / Q000379:methods*; D013234:Stem Cells / Q000166:cytology* / Q000378:metabolism; D014284:Triiodothyronine / Q000378:metabolism*
D003470:Culture Media; D014284:Triiodothyronine; D004247:DNA; D002772:Cholera Toxin; D000225:Adenine; D006854:Hydrocortisone
Adenine; Cholera toxin; Good manufacturing practice; Hydrocortisone; Limbal stem cells; Limbus; Triiodothyronine
Lancet. 1997 Apr 5;349(9057):990-3
9100626
Surv Ophthalmol. 2000 Mar-Apr;44(5):415-25
10734241
Experientia. 1975 Apr 15;31(4):462-4
1091497
Dev Biol Stand. 1991;75:173-5
1665460
Ophthalmology. 2002 Nov;109(11):2004-10
12414406
In Vitro. 1978 Jan;14(1):23-30
624557
Br J Ophthalmol. 2002 Apr;86(4):463-71
11914219
Arch Ophthalmol. 2006 Dec;124(12):1734-40
17159033
Trends Mol Med. 2011 Jan;17(1):1-7
21075055
Invest Ophthalmol Vis Sci. 1983 Oct;24(10):1442-3
6618809
Eye (Lond). 2005 Jul;19(7):813-4; author reply 814-6
15359233
Ophthalmology. 1995 Oct;102(10):1476-85
9097795
J Invest Dermatol. 1982 Jul;79(1):42-7
6177802
N Engl J Med. 2000 Jul 13;343(2):86-93
10891515
Proc Natl Acad Sci U S A. 2005 Jul 5;102(27):9523-8
15983386
Regen Med. 2008 May;3(3):329-42
18462056
Ophthalmology. 2009 Jun;116(6):1048-56
19394701
Ophthalmology. 2005 Mar;112(3):470-7
15745776
Biosci Rep. 2003 Aug;23(4):169-74
14748537
Proc Natl Acad Sci U S A. 1984 Dec;81(24):7802-6
6440145
J Invest Dermatol. 1975 Jul;65(1):52-9
239072
Results Probl Cell Differ. 2012;55:357-94
22918816
Cell. 1975 Nov;6(3):331-43
1052771
Int J Cardiol. 2004 Jun;95 Suppl 1:S29-33
15336842
Stem Cells. 2010 Mar 31;28(3):597-610
20014040
Ophthalmology. 1989 May;96(5):709-22; discussion 722-3
2748125
Ophthalmology. 2003 Oct;110(10):2071; author reply 2071-2
14522807
Curr Eye Res. 1994 Mar;13(3):231-8
8194372
Comp Biochem Physiol Comp Physiol. 1992 Aug;102(4):709-14
1355034
Invest Ophthalmol Vis Sci. 1991 Jul;32(8):2219-33
1712763
Proc Natl Acad Sci U S A. 2001 Mar 13;98(6):3156-61
11248048
Wound Repair Regen. 2001 Nov-Dec;9(6):483-94
11896990
Curr Eye Res. 2012 Jul;37(7):644-53
22559728
Blood. 1997 Feb 1;89(3):776-9
9028307
J Cell Biol. 2007 Jun 18;177(6):1037-49
17562792